News:

This week IPhone 15 Pro winner is karn
You can be too a winner! Become the top poster of the week and win valuable prizes.  More details are You are not allowed to view links. Register or Login 

Main Menu

Ablynx agrees Merck cancer deal worth up to 1.7 billion euros

Started by riky, February 04, 2014, 09:00:17 AM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

riky

Ablynx agrees Merck cancer deal worth up to 1.7 billion euros

<p><a href="http://news.yahoo.com/ablynx-agrees-merck-cancer-deal-worth-1-7-123158035--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/UCU5wMlfjXuyH5Y.Dw.vUg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-02-03T123158Z_1_CBREA120YTF00_RTROPTP_2_SCHERINGPLOUGH-MERCK.JPG" width="130" height="86" alt="A view of the Merck &amp; Co. campus in Linden, New Jersey" align="left" title="A view of the Merck &amp; Co. campus in Linden, New Jersey" border="0" /></a>By Philip Blenkinsop BRUSSELS (Reuters) - Belgian biotech company Ablynx has signed a deal with Merck &amp; Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself. The collaboration involves a new generation of drugs designed to activate the immune system. The first in the field - Bristol-Meyer Squibb's Yervoy - is targeting melanoma, the deadliest form of skin cancer. Rival Merck filed the first part of an application to market its own potential drug for advanced melanoma earlier this month, pushing up its share price.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login
You are not allowed to view links. Register or Login